Carcinoid syndrome overview
|
Carcinoid syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Carcinoid syndrome overview On the Web |
|
American Roentgen Ray Society Images of Carcinoid syndrome overview |
|
Risk calculators and risk factors for Carcinoid syndrome overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Carcinoid (also carcinoid tumour or carcinoid tumor) is slow-growing but often malignant type of neuroendocrine tumour, originating in the cells of the neuroendocrine system. Carcinoid tumours are apudomas that arise from the enterochromaffin cells throughout the gut. They are most commonly found in the foregut (35.6% cases) with lung, bronchus and trachea constituting 27.9% cases from where they rarely metastasise (except in case of pancreas). The next most common affected area is the small intestine especially the midgut (32.1% cases) with the highest proportion from ileum at 14.9% of all cases [as per the PAN-SEER data (1973-1999)]. In cases of metastases it can lead to carcinoid syndrome. This is due to the production of serotonin, which is released into the systemic circulation, which leads to symptoms of cutaneous flushing, diarrhea, bronchoconstriction and right-sided cardiac valve disease.
Historical Perspective
Carcinoid syndrome was first described by Siegfried Oberndorfer, a German pathologist in 1907. Endocrine related properties of carcinoid syndrome was described by Gosset and Masson in 1914.[1][2]
Classification
Carcinoid tumor of the gastrointestinal tract may be classified based on the location into three subtypes (foregut, midgut, or hindgut). Carcinoid tumor of the lung may be classified based on the histology into two subtypes (typical and atypical). Carcinoid tumor of the ovary may be classified into four subtypes (insular, trabecular, strumal, and mucinous type).[3][4]
Pathogenesis
The pathophysiology of carcinoid tumor depends on the histological subtype. Genes involved in the pathogenesis of carcinoid tumor are β-catenin, NF1, and MEN1. Carcinoid tumors originate from neuroendocrine cells. On microscopic histopathological analysis, gastrointestinal carcinoid syndrome is characterized by solid or small trabecular clusters of neuroendocrine cells with uniform nuclei and abundant granular or faintly staining (clear) cytoplasm.
Causes
Common causes of carcinoid syndrome include genetic disorders (multiple endocrine neoplasia type 1 and neurofibromatosis type 1) and genetic mutations (gains involving chromosomes 5, 14, 17, and 19 and losses involving chromosomes 11 and 18).[5]
Differential Diagnosis
Carcinoid syndrome must be differentiated from systemic mastocytosis, medullary thyroid carcinoma, irritable bowel syndrome, malignant neoplasms of the small intestine, benign cutaneous flushing, and recurrent idiopathic anaphylaxis.[6]
Epidemiology and Demographics
The incidence of carcinoid syndrome is estimated to be 2 cases per 100,000 individuals worldwide.[7] Carcinoid syndrome is a disease that tends to affect the elderly population. The median age at diagnosis is 60.9 years.[8] Females are more commonly affected with carcinoid syndrome than males. Carcinoid syndrome usually affects individuals of the Caucasian race. African American, Latin American, and Asian individuals are less likely to develop carcinoid syndrome.[8]
Risk Factors
Common risk factors in the development of carcinoid syndrome include age (50 years or older), gender (female), multiple endocrine neoplasia type 1, neurofibromatosis type 1, atrophic gastritis, pernicious anemia, and Zollinger-Ellison syndrome.[9]
Screening
There is insufficient evidence to recommend routine screening for carcinoid tumor.[10]
Natural History
If left untreated, patients with carcinoid syndrome may progress to develop flushing, diarrhea, and carcinoid heart disease (valvular heart disease and cardiac dysrythmias). Common complications of carcinoid tumor include increased risk of falls and injury (from hypotension), bowel obstruction, gastrointestinal bleeding, right-sided heart failure, and fibrosis of the tricuspid valve and pulmonary valve, more rarely the mitral valve in cases with left sided involvement. Prognosis is generally good, and the 5-year survival rate of patients with carcinoid syndrome is approximately 69.7%.[8]
References
- ↑ Tsoucalas G, Karamanou M, Androutsos G (2011). "The eminent German pathologist Siegfried Oberndorfer (1876-1944) and his landmark work on carcinoid tumors". Ann Gastroenterol. 24 (2): 98–100. PMC 3959292. PMID 24713679.
- ↑ Swiryn S, Hueter DC (1986). "The electrocardiogram in esophageal impaction". JAMA. 255 (15): 2067–8. PMID 3959292.
- ↑ Ovarian carcinoid tumours. Dr Aditya Shetty and Dr Yuranga Weerakkody et al. Radiopaedia 2015. http://radiopaedia.org/articles/ovarian-carcinoid-tumours
- ↑ Carcinoid tumours of the lung. Dr Henry Knipe and Dr Yuranga Weerakkody et al. Radiopaedia 2015. http://radiopaedia.org/articles/carcinoid-tumours-of-the-lung
- ↑ Molecular genetics. National Cancer Institute. http://www.cancer.gov/types/gi-carcinoid-tumors/hp/gi-carcinoid-treatment-pdq
- ↑ Metcalfe DD (2000). "Differential diagnosis of the patient with unexplained flushing/anaphylaxis". Allergy Asthma Proc. 21 (1): 21–4. PMID 10748948.
- ↑ Epidemiology of carcinoid tumor. National cancer institute. http://www.cancer.gov/types/gi-carcinoid-tumors/hp/gi-carcinoid-treatment-pdq
- ↑ 8.0 8.1 8.2 Maggard MA, O'Connell JB, Ko CY (2004). "Updated population-based review of carcinoid tumors". Ann Surg. 240 (1): 117–22. PMC 1356383. PMID 15213627.
- ↑ Health history can affect the risk of gastrointestinal carcinoid tumors. National Cancer Institute. http://www.cancer.gov/types/gi-carcinoid-tumors/patient/gi-carcinoid-treatment-pdq
- ↑ Can gastrointestinal carcinoid tumors be found early?. American cancer society. Cancer.org. http://www.cancer.org/acs/groups/cid/documents/webcontent/003102-pdf.pdf